Study to test AutoPulse non-invasive cardiac support pump in comparison to manual chest compressions alone
ZOLL Medical has reported that the first planned review of data related to patient enrollment in the CIRC (Circulation Improving Resuscitation Care) trial by the Data Safety Monitoring Board (DSMB) has been completed and the trial is proceeding with patient enrollment as originally designed.
Data from the international trial, that is testing the effectiveness of the FDA-cleared AutoPulse non-invasive cardiac support pump in comparison to manual chest compressions alone, was fully reviewed by the Data Safety Monitoring Board. Research is going on whether AutoPulse-integrated chest compressions are superior or equivalent to manual compressions alone for patients suffering cardiac arrests tied to heart conditions.
Richard Packer, chairman and chief executive officer of ZOLL, said: “We are pleased with the significant progress the CIRC Trial is making. We note that an earlier trial of the AutoPulse, ‘ASPIRE’, was halted prematurely after its first review due to futility and concerns about safety, and if similar issues had been identified with CIRC, the DSMB would have halted enrollment. Instead, we got a clean check-up and are continuing ahead in this important effort.
“While some clinicians are waiting for the results of this trial to validate the contribution mechanical CPR can make to improving outcomes from sudden cardiac death, recent reports presented at the American Heart Association Resuscitation Science Symposium add to the continuing science supporting the AutoPulse.As the economy improves we look for the growth of the AutoPulse to accelerate.”
The AutoPulse has been commercially available for over four years and is in use worldwide, said the company.